It's never on anyone's to-do list to carefully look at all the statements they're receiving. Most tax filers either hand those documents over to a professional or, if they are do-it-yourselfers, ...

B. Riley initiates Foghorn Therapeutics at buy with $10 price target, citing promising development of SMARCA2 inhibitors for ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) had its target price lowered by equities researchers at Citigroup from ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...